Free Trial
→ This is the “End of Tesla” as we know it… (From Brownstone Research) (Ad)tc pixel
NASDAQ:ONCO

Onconetix 8/14/2025 Earnings Report

Onconetix logo
$3.21 -0.18 (-5.31%)
Closing price 04:00 PM Eastern
Extended Trading
$3.22 +0.00 (+0.16%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Onconetix EPS Results

Actual EPS
-$4.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Onconetix Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Onconetix Announcement Details

Quarter
Date
8/14/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Onconetix's next earnings date is estimated for Monday, December 8, 2025, based on past reporting schedules.

Conference Call Resources

Onconetix Earnings Headlines

No deal: Cincinnati-based public firm, target terminate merger plans
September 27 at 12:28 AM  |  bizjournals.comhttps://www.bizjournals.com/cincinnati/news/2025/09/26/onconetix-ocuvex-terminate-merger-veru-payment.html
Onconetix, Inc.: Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
September 27 at 9:52 AM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-09/66548579-onconetix-inc-joint-press-release-onconetix-and-ocuvex-announce-mutual-termination-of-merger-agreement-399.htm
This is the “End of Tesla” as we know it…
Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla call alone could have made readers 21 TIMES THEIR MONEY, if they listened to his recommendation. Don't miss his next big prediction.tc pixel
September 29 at 2:00 AM  |  Brownstone Research (Ad)
Onconetix, Ocuvex announce mutual termination of merger agreement
September 27 at 9:52 AM  |  msn.comhttps://www.msn.com/en-us/money/general/onconetix-ocuvex-announce-mutual-termination-of-merger-agreement/ar-AA1NmVkj
Onconetix announces financing through private placement, debt settlement
September 26 at 6:48 PM  |  msn.comhttps://www.msn.com/en-us/money/markets/onconetix-announces-financing-through-private-placement-debt-settlement/ar-AA1NmZR8
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
September 26 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/26/3157006/0/en/onconetix-announces-financing-through-a-12-9-million-private-placement-of-series-d-preferred-stock-and-warrants-termination-of-merger-agreement-with-ocuvex-inc-and-settlement-of-8-.html
See More Onconetix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Onconetix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Onconetix and other key companies, straight to your email.

About Onconetix

Onconetix (NASDAQ:ONCO), a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

View Onconetix Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles